Main Sequence Ventures invests in ambitious founders creating the next set of global industries leveraging deep tech or frontier technologies. The firm is backed by the Australian National Science Agency, CSIRO, the Australian Federal Government, and private investors.  All Main Sequence investments leverage world-leading research from Australian public research organizations such as CSIRO, any of Australia's 41 universities or its multitude of other industry research agencies.

Main Sequence Ventures

Australian Medical Angels is an Angel Syndicate that connects investors with early-stage health technology companies in diverse areas. The firm leverages its medical expertise to identify and support innovative companies in the healthcare sector, including biotechnology, medical devices, digital health, and pharmaceuticals. By providing capital and mentorship, Australian Medical Angels aims to accelerate the growth of healthcare startups and improve patient outcomes. The network comprises healthcare professionals passionate about advancing medical innovation and supporting entrepreneurs in the industry.

Australian Medical Angels

EVP is an early stage venture capital firm based in Sydney Australia with c. $300M FUM across four fund vintages. Our most recent fund was launched in December 2022 and is a $100M fund. The fund targets early Series-A investments initially with cheque sizes in the range of $0.5 – $5.0 million.  Our funds invest in software, are sector agnostic and have a focus on Australian based B2B SaaS companies. Over the years, we’ve backed brilliant founders building global software companies like SiteMinder, Deputy, Ignition and Shippit. We make high conviction investments, underpinned by ambition, pragmatism and a deep understanding of the software journey.

Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Their goal is to provide money and mentoring to the life science community to achieve superior returns for their group, and more clinical innovation for the community.

Mass Medical Angels

Commonwealth Scientific and Industrial Research Organization is the federal government agency for scientific research.    It manages three national research facilities, including the Australian Animal Health Laboratory at Geelong; Australia Telescope at Parkes, Coonabarabran, and Narrabri; and the oceanographic research vessel Southern Surveyor.    CSIRO’s research highlights include the invention of atomic absorption spectroscopy, development of the first commercially successful polymer banknote, the invention of the insect repellent in Aerogard, and the introduction of a series of biological controls into Australia, such as the introduction of myxomatosis and rabbit calicivirus which causes rabbit haemorrhagic disease for the control of rabbit populations.    Employing nearly 6,500 staff, CSIRO maintains more than 50 sites across Australia and biological control research stations in France and Mexico. It was founded in 1926 originally as the Advisory Council of Science and Industry.

CSIRO

Giant Leap Fund is Australia’s first venture capital fund that is 100% dedicated to investing in impact startups – rapidly scalable businesses that blend financial returns with real and measurable social and environmental benefits. We invest across the following themes: Sustainable living, health and wellbeing, and empowering people. In 2021, Giant Leap spun out from IIG into a new independent entity solely focussed on Impact Venture Capita. It also started raising its second fund, Giant Leap Fund II. Giant Leap is currently investing from Giant Leap Fund II and will continue its mission to back game-changing founders re-imagining industries and using business as a force for good.

Giant Leap Fund

Coviu

Coviu is a telehealth startup that helps doctors and health practitioners with AI-backed clinical tools to make the video calling experience with the patient even better than actually seeing the patient in real life. The company offers consultations regarding cardiology, dentistry, dermatology, diabetes, dietetics, endocrinology, Endoscopy. general practice, beauty, naturopathy, nutrition, homeopathy, occupational therapy, child health and pediatrics, orthopedics, psychology, psychotherapy, plastic surgery, speech and language therapy, urology, women’s health, and many more. Its video consultations are enhanced with a range of in-call clinical tools, and its software integrates seamlessly with a range of practice management systems.

<div>Australia-based Coviu provides telehealth technology solutions such as video conferencing, remote patient monitoring, group telehealth consultations, and phone consultations. The platform comes with digital tools developed by third parties to supplement its functionality.&nbsp; Its online platform also has an app marketplace for clinicians to download additional tools.&nbsp;</div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Super Duper Publications Announces Partnership With Coviu to Empower Speech-Language Pathologists With Enhanced Teletherapy Solutions

<div>
 
 Australia-based Coviu provides telehealth technology solutions such as video conferencing, remote patient monitoring, group telehealth consultations, and phone consultations. The platform comes with digital tools developed by third parties to supplement its functionality.&nbsp; Its online platform also has an app marketplace for clinicians to download additional tools.&nbsp;
 
 
 
 
 In August 2022 the company began offering its virtual care platform in the US. As of August 2022 the company provides its services globally and is used by over 90,000 clinicians worldwide resulting in an average of over 14,000 daily virtual consultations. 
 
 
 
</div>

<div>
 
 Nice Healthcare is a US based telehealth company with a focus on primary care services to business-to-business (B2B) clients. Once the employer signs its employees with Nice (at a cost of USD 30 to USD 36 per employee per month), employees do not have to incur out of pocket expenses for Nice services and can schedule virtual or home visits within the time frames specified by the company. It connects patients with practitioners through a mobile app over video calls or text messages. Members can also request home visits which will be completed within a few hours, as claimed by the company. As of March 2022, Nice was operating in twelve states, and had over 400 small and medium enterprises (SMEs).
 
 
 In March 2022, the company raised USD 30 million in Series A financing led by DNA Capital which has been earmarked to expand its platform&rsquo;s reach among small and medium businesses. Additionally, the company is hiring three members for its management team to support the continuing growth of the organization.
 
 
 
</div>

Nice Healthcare

Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications.Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.

Amicomed

Winston is a men’s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients.The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.

Winston

<div>
 
 Dialogue partners with employers and health insurers to offer telehealth services to their employees and members. The users have 24/7 access to doctors, nurses, and other healthcare professionals via audio, video, and chat options for wide arrays of physical and mental health needs, artificial intelligence-enabled (AI-enabled) triage, referrals, and prescription renewals. 
 
 
 The company launched its trademarked Integrated Health Platform in January 2021 to consolidate its virtual care, wellness programs, mental healthcare services, and Employee Assistance Program (EAP) onto a single platform. The company claims to be the only integrated health and wellness B2B platform in Canada. 
 
 
 Key Customers and partnerships
 
 
 Dialogue had direct relationships with over 2,000 customers across Canada and Germany as of December 2020 and served around 50,000 organizations through these partnerships. In addition, the number of members with access to the virtual platform topped 1 million in January 2021. 
 
 
 Fundings and financials
 
 
 As of March 2021, Dialogue was planning to raise CAD 100 million (USD 80 million) from an initial public offering that will be listed on the Toronto Stock Exchange under the ticker symbol &ldquo;CARE.&rdquo; 
 
 
 In Q2 2023, net losses reduced significantly YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022. Top-line revenue met internal expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million), driven by &nbsp;an increase in new members (by 18.6% YoY), 
 an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac.
 
 Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
 <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
 acquired by financial services company Sun Life Financial
 </a>
 for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec. 
 
 
 
</div>

Dialogue

Grin offers telemedicine and remote monitoring services for orthodontic needs such as braces and teeth straightening. Patients can conduct self-scans (using a Grin device made available to patients in collaboration with 3M) which can be connected to their smartphones and share the feed with orthodontists to access dental solutions. The company plans to go to a subscription-based model after the pandemic. The app also encourages patients to have a 40-second check monthly and share the scan with a dentist in order to allow patients to regularly maintain their dental hygiene.Grin is the only Telehealth disruptor covered on the hub that provides virtual orthopaedic consultations.Funding and financialsIn April 2021, the New York-based teledental platform concluded a seed funding of USD 14 million, and the funds will be allocated to develop additional functionalities by building out its technology. The proceeds will also be used to scale up its team, expand its geographic footprint, and add doctors to the company’s orthodontic partner network.

Grin

Real-time collection of patients’ health-related data using any remote patient monitoring device combined with general telemedicine services to reduce readmission rates. 


A platform that facilitates the transmission of patient data to different locations for further evaluation and interpretation by medical specialists. 


A digital platform that offers specialty care services to address the specific needs of a patient or demographic, including consultations where patients are generally reluctant to meet practitioners face-to-face.

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app. 

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers. 

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

Coviu

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless